Income statement
USD
Annual
| Metric | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | -221K | -60K | -222K |
| Operating Income | -23M | -4M | -2M | -2M | -2M |
| EBITDA | -23M | -4M | -2M | -2M | -1M |
| Net Income | -23M | -4M | -2M | -2M | -1M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Petlife Pharmaceuticals, Inc. (PTLF) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +17.5%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +17.5%, free cash flow -110.0% with operating margin 0.0% and ROIC 3410.5%. Stock Foundry combines PTLF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PTLF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PTLF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PTLF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$1.2M
+23.2% YoY
Free Cash Flow
-$137.1K
+48.7% YoY
Revenue Growth
+0.0%
EPS Growth
+17.5%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | -221K | -60K | -222K |
| Operating Income | -23M | -4M | -2M | -2M | -2M |
| EBITDA | -23M | -4M | -2M | -2M | -1M |
| Net Income | -23M | -4M | -2M | -2M | -1M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|
| Cash & Equivalents | 54K | 1K | 0 | 7K | 0 |
| Total Assets | 55K | 1K | 5K | 17K | 0 |
| Total Liabilities | 1M | 3M | 371K | 0 | 0 |
| Shareholder Equity | -1M | -3M | -365K | 17K | 0 |
| Total Debt | 717K | 153K | 0 | 0 | 138K |
| Net Debt | 663K | 152K | 0 | -7K | 138K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
137K
+48.7% YoY
Capital Expenditures
3
Free Cash Flow
137K
+48.7% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
1007.6%
Debt / Equity
-0.52x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.